PERTZYE
PERTZYE is a pancreatic enzyme replacement therapy indicated for the treatment of exocrine pancreatic insufficiency. The medication is approved for use in both adult and pediatric patient populations. It serves a therapeutic role by providing the digestive enzymes that are normally secreted by the pancreas to facilitate the breakdown of nutrients.
How PERTZYE Works
The medication contains a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats, proteins, and starches in the duodenum and proximal small intestine. These enzymes break down fats into monoglycerides and fatty acids, proteins into peptides and amino acids, and starches into dextrins and short-chain sugars. By performing these catalytic actions, the drug mimics the physiological activity of endogenous pancreatic enzymes to aid digestion.
Details
- Status
- Prescription
- First Approved
- 2012-05-17
- Routes
- ORAL
- Dosage Forms
- CAPSULE, DELAYED RELEASE
Companies
PERTZYE Approval History
What PERTZYE Treats
1 indicationsPERTZYE is approved for 1 conditions since its original approval in 2012. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Exocrine Pancreatic Insufficiency
Drugs Similar to PERTZYE
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PERTZYE FDA Label Details
ProIndications & Usage
FDA Label (PDF)PERTZYE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. PERTZYE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.